ArticleTherapeutic advances in psychopharmacology2026
Predicting the blood concentration of levetiracetam in people with epilepsy using machine learning and real-world data.
Article in Therapeutic advances in psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prediction of Zonisamide Concentration in Pediatric Patients With Epilepsy: A Machine Learning Approach.CNS neuroscience & therapeutics · 2026Article
- Therapeutic drug monitoring of zonisamide in children with epilepsy: development and validation of a precise binary prediction model.Frontiers in pharmacology · 2026Article
- Prediction of Lithium Therapeutic Target Attainment in Adolescents Using an XGBoost Model: A Single-Center Retrospective Study.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Levetiracetam is an antiepileptic drug widely used to treat partial and generalized seizures in clinicians. The effectiveness and safety of levetiracetam in individuals with epilepsy are affected by various complex factors, including physiological condition and genetic variations. Therapeutic drug monitoring (TDM) serves as a valuable tool to optimize levetiracetam treatment and enable individualized treatment for patients with epilepsy. Machine learning is now a powerful tool for data processing and analysis. However, there is a lack of studies on the application of machine learning methods for the prediction of levetiracetam blood concentration in epilepsy patients. Objective: The aim of this study is to develop machine learning models to predict levetiracetam concentration in epilepsy patients, utilizing a web application for clinical dosage adjustment. Design: This is a retrospective study enrolling patients diagnosed with seizures and given levetiracetam therapy at Beijing Hospital from January 1, 2024, to May 22, 2025. Method: This study included 153 cases of levetiracetam TDM data in patients with epilepsy. A total of 47 variables from five dimensions of enrolled patients were collected, and sequential forward selection was implemented to screen the optimum variable subsets related to levetiracetam TDM. The prediction abilities of multiple machine learning models were compared based on subset variables. The optimal prediction model was subsequently chosen to calculate and rank the importance scores of each variable, and SHapley Additive exPlanations (SHAP) was adopted to visually interpret the impact of variables on levetiracetam concentration. Results: The median value of levetiracetam TDM was 10.95 μg/mL, and the levetiracetam TDM of 72 cases (47.1%) was found to be lower than the recommended range. Eleven variables were finally identified as the optimal subset variables. Using the eleven variables as the covariates, the eXtreme Gradient Boosting (XGBoost) algorithm performed best ( Conclusion: Our study found that XGBoost is a valuable artificial intelligence instrument for predicting levetiracetam concentration. Daily dose and age were two significant covariates influencing serum concentration. This work is the first study to analyze the levetiracetam concentration data from the real world and predict the blood concentration using machine learning techniques, which provides guidance for the drug adjustment in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.